drugset / Trial / NCT05655520
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)
Timeline
- Start
- 2022-12-14
- Primary completion
- 2025-01-20
- Completion
- 2025-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalzanemdor | Small molecule | 0.9 mg | Oral |